Cingulate Price Target Lowered to $16 at Roth Capital

jueves, 20 de noviembre de 2025, 7:42 am ET1 min de lectura
CING--

Roth Capital analyst Boobalan Pachaiyappan lowered the price target on Cingulate (CING) to $16 from $17 and maintained a Buy rating. The firm is adjusting its model as Cingulate may choose to raise capital during the next 6 to 12 months. The company is increasing pre-commercialization efforts for CTx-1301 through its Indegene partnership.

Cingulate Price Target Lowered to $16 at Roth Capital

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios